Efficient synthetic inhibitors of anthrax lethal factor

Martino Forino, Sherida Johnson, Thiang Y. Wong, Dmitri Rozanov, Alexei Y. Savinov, Wei Li, Roberto Fattorusso, Barbara Becattini, Andrew J. Orry, Dawoon Jung, Ruben A. Abagyan, Jeffrey W. Smith, Ken Alibek, Robert C. Liddington, Alex Y. Strongin, Maurizio Pellecchia

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxican against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.

Original languageEnglish (US)
Pages (from-to)9499-9504
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number27
DOIs
StatePublished - Jul 5 2005
Externally publishedYes

Fingerprint

Bacillus anthracis
Metalloproteases
Anthrax
Emergency Treatment
Anti-Bacterial Agents
Inhalation anthrax
anthrax toxin
Therapeutics
In Vitro Techniques

Keywords

  • Drug design
  • Fragment-based design
  • Metalloprotease
  • NMR
  • Protective antigen

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Efficient synthetic inhibitors of anthrax lethal factor. / Forino, Martino; Johnson, Sherida; Wong, Thiang Y.; Rozanov, Dmitri; Savinov, Alexei Y.; Li, Wei; Fattorusso, Roberto; Becattini, Barbara; Orry, Andrew J.; Jung, Dawoon; Abagyan, Ruben A.; Smith, Jeffrey W.; Alibek, Ken; Liddington, Robert C.; Strongin, Alex Y.; Pellecchia, Maurizio.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 27, 05.07.2005, p. 9499-9504.

Research output: Contribution to journalArticle

Forino, M, Johnson, S, Wong, TY, Rozanov, D, Savinov, AY, Li, W, Fattorusso, R, Becattini, B, Orry, AJ, Jung, D, Abagyan, RA, Smith, JW, Alibek, K, Liddington, RC, Strongin, AY & Pellecchia, M 2005, 'Efficient synthetic inhibitors of anthrax lethal factor', Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9499-9504. https://doi.org/10.1073/pnas.0502733102
Forino, Martino ; Johnson, Sherida ; Wong, Thiang Y. ; Rozanov, Dmitri ; Savinov, Alexei Y. ; Li, Wei ; Fattorusso, Roberto ; Becattini, Barbara ; Orry, Andrew J. ; Jung, Dawoon ; Abagyan, Ruben A. ; Smith, Jeffrey W. ; Alibek, Ken ; Liddington, Robert C. ; Strongin, Alex Y. ; Pellecchia, Maurizio. / Efficient synthetic inhibitors of anthrax lethal factor. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 27. pp. 9499-9504.
@article{b38c531537d3457dbd0569f985cba0b1,
title = "Efficient synthetic inhibitors of anthrax lethal factor",
abstract = "Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxican against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.",
keywords = "Drug design, Fragment-based design, Metalloprotease, NMR, Protective antigen",
author = "Martino Forino and Sherida Johnson and Wong, {Thiang Y.} and Dmitri Rozanov and Savinov, {Alexei Y.} and Wei Li and Roberto Fattorusso and Barbara Becattini and Orry, {Andrew J.} and Dawoon Jung and Abagyan, {Ruben A.} and Smith, {Jeffrey W.} and Ken Alibek and Liddington, {Robert C.} and Strongin, {Alex Y.} and Maurizio Pellecchia",
year = "2005",
month = "7",
day = "5",
doi = "10.1073/pnas.0502733102",
language = "English (US)",
volume = "102",
pages = "9499--9504",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "27",

}

TY - JOUR

T1 - Efficient synthetic inhibitors of anthrax lethal factor

AU - Forino, Martino

AU - Johnson, Sherida

AU - Wong, Thiang Y.

AU - Rozanov, Dmitri

AU - Savinov, Alexei Y.

AU - Li, Wei

AU - Fattorusso, Roberto

AU - Becattini, Barbara

AU - Orry, Andrew J.

AU - Jung, Dawoon

AU - Abagyan, Ruben A.

AU - Smith, Jeffrey W.

AU - Alibek, Ken

AU - Liddington, Robert C.

AU - Strongin, Alex Y.

AU - Pellecchia, Maurizio

PY - 2005/7/5

Y1 - 2005/7/5

N2 - Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxican against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.

AB - Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxican against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.

KW - Drug design

KW - Fragment-based design

KW - Metalloprotease

KW - NMR

KW - Protective antigen

UR - http://www.scopus.com/inward/record.url?scp=22144478634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144478634&partnerID=8YFLogxK

U2 - 10.1073/pnas.0502733102

DO - 10.1073/pnas.0502733102

M3 - Article

VL - 102

SP - 9499

EP - 9504

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 27

ER -